Abstract Apabetalone (RVX-208) is an epigenetic regulator developed to treat
cardiovascular disease (CVD) that targets BET proteins. Through transcriptional regulation …

Abstract Background Apabetalone (RVX-208) is a bromodomain and extraterminal protein
inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac …

Background Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a
high residual risk for experiencing a major adverse cardiac event. Dysregulation of …

A wealth of evidence indicates a fundamental role for inflammation in the pathogenesis of
cardiovascular disease (CVD), contributing to the development and progression of …

C3 is the central component of the complement system and activation of C3 via any of the
three major activation pathways—the classical, the lectin and the alternative pathways …

Function and regulation of the complement system in cardiovascular diseases Page 1 See
discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/6346822 …

Cardiovascular diseases are the leading cause of death globally, and atherosclerosis is the
major contributor to the development and progression of cardiovascular diseases. Immune …

While complement is the most important component of humoral autoimmunity, and
inflammation plays a key role in atherosclerosis, relatively few studies have looked at …

High density lipoproteins (HDL), through activity of the main protein component
apolipoprotein AI (ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing …

Background Complement activation contributes significantly to inflammation-related damage
in the heart after acute myocardial infarction. Knowledge on factors that regulate …